Faricimab: An Emerging Therapy for the Treatment of Neovascular Age-related Macular Degeneration

Aziz, Aamir; Khan, Majid; Baumal, Caroline R.; Khanani, Arshad M.

doi:10.17925/opht.2021.15.1.23

Cited by 1 publication

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… A single injection of faricimab results in rapid improvement in all anatomic parameters in treatment-naïve and previously treated patients with nAMD and DME [ 8 – 11 , 27 , 28 ]. Most patients switching from aflibercept 2 mg to faricimab experience reductions in CST/IRF/SRF/PED, along with stable or improved vision with the potential for extended treatment intervals in both nAMD and DME [ 9 – 11 , 27 , 28 ]. Notal Oct Analyzer (NOA) fluid quantification sub-study has indicated that faricimab offers advantages in improving fluid status of patients with nAMD [ 29 ].…”

Section: Lessons From the Real Word Datamentioning

confidence: 99%

“…A single injection of faricimab results in rapid improvement in all anatomic parameters in treatment-naïve and previously treated patients with nAMD and DME [ 8 – 11 , 27 , 28 ].…”

Section: Lessons From the Real Word Datamentioning

confidence: 99%

“…Most patients switching from aflibercept 2 mg to faricimab experience reductions in CST/IRF/SRF/PED, along with stable or improved vision with the potential for extended treatment intervals in both nAMD and DME [ 9 – 11 , 27 , 28 ].…”

Section: Lessons From the Real Word Datamentioning

confidence: 99%

See 2 more Smart Citations

Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME

Penha,

Masud,

Khanani

et al. 2024

Int J Retin Vitr

View full text Add to dashboard Cite

Management of vitreoretinal disorders (e.g., neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME]) have assumed the standard therapy of lifelong anti-VEGF injections with drugs like aflibercept, brolucizumab, ranibizumab and bevacizumab. However, the burden imposed on patients is a major deterrent for continual therapy and recovery. Faricimab, a bispecific antibody, blocking both VEGF-A and Ang-2 molecules, produces a comparable functional and anatomical results, with less injections, significantly reducing patient burden. Visual acuity, safety, adverse effects, and anatomical outcomes are discussed in the pivotal clinical trials (YOSEMITE/RHINE and TENAYA/LUCERNE), and early data from real-world studies (TRUCKEE, TAHOE, FARWIDE-DME, FARETINA and others). In YOSEMITE and RHINE, faricimab demonstrated non-inferior vision gains, better anatomical outcomes compared to aflibercept every 8 weeks. Faricimab in the personalized treatment interval (PTI), after week 96, achieved 12-week interval in 78.1% of the patients and 16-week interval in 62.3%. TENAYA and LUCERNE reported comparable best corrected visual acuity (BCVA) improvement and better anatomic outcomes during head-to-head phase, parallel to aflibercept, at its 8-week treatment schedule. Faricimab in the PTI regimen, after week 96 achieved 12-week interval in 77.8% of the patients and 16-week interval in 63.1%. Safety of faricimab has been comparable to aflibercept in these pivotal trials. Real-world data supports the data from the pivotal studies regarding the efficacy and safety profile of faricimab in heterogenous real world patient population. Moreover, in previously treated patients, it also demonstrated a faster fluid resolution, good safety profile. Considering faricimab has demonstrated anatomic and durability benefit in the treatment of nAMD and DME, additional data from ongoing extension clinical trials, AVONELLE-X and RHONE-X will help understand longer term outcomes for patients treated with faricimab as well as patients switching from aflibercept to faricimab after finishing the pivotal trials. Longer term data from the real-world studies will also continue to contribute to our understanding of long-term efficacy, safety and durability in the real world patient population.

show abstract

Section: Lessons From the Real Word Datamentioning

confidence: 99%

“…A single injection of faricimab results in rapid improvement in all anatomic parameters in treatment-naïve and previously treated patients with nAMD and DME [ 8 – 11 , 27 , 28 ].…”

Section: Lessons From the Real Word Datamentioning

confidence: 99%